AACR-NCI-EORTC 2025: First-in-class oral macrocyclic cyclin D1-selective inhibitors demonstrate anti-tumor activity in cyclin D1-dependent tumors October 23, 2025 READ MORE
Circle Pharma Unveils First Preclinical Data from Cyclin D1 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics October 23, 2025 READ MORE
Circle Pharma Announces Upcoming Poster Presentation Highlighting the Anti-tumor Potential of Cyclin D1 RxL Inhibition at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics October 14, 2025 READ MORE
AACR Conference on Pediatric Cancer: Investigating the cyclin A/B RxL inhibitor CID-078 in pediatric cancers with RB1 loss and high E2F1 October 1, 2025 READ MORE
Circle Pharma Announces Poster Presentation Highlighting the Potential of CID-078, a First-in-class Oral Cyclin A/B RxL Inhibitor, at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer September 25, 2025 READ MORE
Circle Pharma Announces Agreement with Lilly to Further Enhance AI/ML Capabilities and Accelerate Development of New Oral Macrocycle Therapies September 9, 2025 READ MORE
